Израильде ең жақсы маммологияның маммологтар - ЖОҒ-4 дәрігерлер

Ішкі аурулар және кардиология салаларында сертификатталған доктор Абаллай Сураски медициналық орталығына 20 жылдан астам клиникалық тәжірибесін әкеледі.

• Кардиология, пульмонология және критикалық жағдайлар медицинасы бойынша маманданған
• Аурулар мен медициналық жағдайлардың кең спектрін емдейді
• Пациенттерге испан және ағылшын тілдерінде кеңес береді

Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.

She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.

Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.

Professor Dov Zippel is a general surgeon and surgical oncologist. He specializes in breast disease and melanoma. He leads the Meirav Breast Center at Sheba Medical Center. He also serves at the Ella Lemelbaum Institute for Immuno-Oncology. In 2025, Forbes Israel named him to its Best Doctors list.

Expertise: advanced care for benign and malignant breast tumors. Minimally invasive and breast-conserving surgery. Surgical treatment of melanoma and other skin cancers.

Accreditations: MD, Tel Aviv University. Residency in general surgery, Sheba Medical Center. Fellowship in surgical oncology, University of Calgary. Board-certified in general surgery and surgical oncology. Research includes intact breast lesion excision and perioperative BRAF inhibitors for stage III melanoma.